|
LIVE WEBINAR: Tuesday, April 20, 2021, 8:30 AM – 10:00 AM Eastern Time
Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers13th Annual Oncology Grand Rounds NCPD Webinar SeriesBreast Cancer
Faculty
Carey K Anders, MD Professor of Medicine Medical Director of the Duke Center of Brain and Spine Metastases Duke Cancer Institute Durham, North Carolina Kathy D Miller, MD Ballvé-Lantero Professor Division of Hematology/Oncology Associate Director for Clinical Research The Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana Sara M Tolaney, MD, MPH Associate Director, Susan F Smith Center for Women’s Cancers Director of Clinical Trials, Breast Oncology Director of Breast Immunotherapy Clinical Research Senior Physician Breast Oncology Program Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Nurse Case Presentations By
Gretchen Santos Fulgencio, MSN, FNP-BC University of California, San Francisco Berkeley, California Allie Hershey, MSN, RN, ANP-BC, AOCNP Oncology Nurse Practitioner, Breast Oncology Susan F Smith Center for Women’s Cancers Dana-Farber Cancer Institute Boston, Massachusetts Kelly Leonard, MSN, FNP-BC Family Nurse Practitioner Dana-Farber Cancer Institute Boston, Massachusetts Moderator Neil Love, MD Research To Practice Miami, Florida Tuesday, April 20, 2021 Topics to Be Discussed
Target Audience
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. Credit Designation Statements This educational activity for 1.5 contact hours is provided by RTP. This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours. To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity. Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2021/BreastCancer/ILNA Unlabeled/Unapproved Uses Notice There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Anders – Consulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Eisai Inc, Elucida Oncology Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Novartis, Seagen Inc; Contracted Research: G1 Therapeutics, Lilly, Merck, Nektar, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Tesaro, A GSK Company, The Zion Pharma; Royalties: Jones and Bartlett Learning. Dr Miller – Consulting Agreements: AbbVie Inc, Athenex; Contracted Research: Astex Pharmaceuticals, BBI Solutions, CytomX Therapeutics, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Merck, Roche Laboratories Inc. Dr Tolaney – Consulting Agreements: AstraZeneca Pharmaceuticals LP, Athenex, Bristol-Myers Squibb Company, Certara, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Kyowa Kirin Co Ltd, Lilly, Merck, Mersana Therapeutics, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, OncoSec Medical, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Data and Safety Monitoring Board/Committee: Odonate Therapeutics. CONTRIBUTING NURSES — Ms Fulgencio, Ms Hershey and Ms Leonard had no relevant conflicts of interest to disclose. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc. RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Lilly, Novartis and Seagen Inc. |